ArticleBritish journal of pharmacology2018
Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.
Article in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Trial
- Computational Engineering of siderocalin to modulate its binding affinity to the antihypertension drug candesartan.Journal of structural biology · 2025Article
- Current Landscape of Hepcidin Therapeutics.Advances in experimental medicine and biology · 2025Review
- Iron deficiency and supplementation in heart failure.Nature reviews. Cardiology · 2024Review
- Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease.Kidney international reports · 2021Review
- The Role of Iron in Benign and Malignant Hematopoiesis.Antioxidants & redox signaling · 2021Review
- Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders.British journal of haematology · 2021Review
- The multifaceted role of iron in renal health and disease.Nature reviews. Nephrology · 2020Review
- Iron metabolism and iron disorders revisited in the hepcidin era.Haematologica · 2020Review
- Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Review
- Unraveling Hepcidin Plasma Protein Binding: Evidence from Peritoneal Equilibration Testing.Pharmaceuticals (Basel, Switzerland) · 2019Article
- Hepcidin-ferroportin axis in health and disease.Vitamins and hormones · 2019Review
- Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases.Pharmaceuticals (Basel, Switzerland) · 2018Review
- [Advances on diagnosis and treatment of anemia of inflammation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
- Anemia in the Elderly.HemaSphere · 2018Review
- AnticalinBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2018Review
- Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.British journal of pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeAnaemia of chronic disease (ACD) has been linked to iron-restricted erythropoiesis imposed by high circulating levels of hepcidin, a 25 amino acid hepatocyte-derived peptide that controls systemic iron homeostasis. Here, we report the engineering of the human lipocalin-derived, small protein-based anticalin PRS-080 hepcidin antagonist with high affinity and selectivity. EXPERIMENTAL APPROACH: Anticalin- and hepcidin-specific pharmacokinetic (PK)/pharmacodynamic modelling (PD) was used to design and select the suitable drug candidate based on t KEY
resultsPRS-080 had a hepcidin-binding affinity of 0.07 nM and, after coupling to 30 kD PEG (PRS-080-PEG30), a t CONCLUSIONS AND IMPLICATIONS: In conclusion, we developed a dose-dependent and safe approach for the direct suppression of hepcidin, resulting in prolonged iron mobilization to alleviate iron-restricted erythropoiesis that can address the root cause of ACD. PRS-080-PEG30 is currently in early clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.